Why the study?
Does atrasentan improve coronary microvascular endothelial function in patients with early atherosclerosis?
Does atrasentan improve coronary microvascular endothelial function in patients with early atherosclerosis?
Atrasentan improves coronary microvascular endothelial function in patients with early atherosclerosis, highlighting the role of the endothelin system.
May support endothelin antagonism in early atherosclerosis; leaves open randomized confirmation before practice change.
This study demonstrates that 6-month treatment with atrasentan improves coronary microvascular endothelial function and supports the role of the endogenous endothelin system in the regulation of endothelial function in early atherosclerosis in humans. Clinical Trial Registration Information- URL: http://www.clinicaltrials.gov. Unique identifier: NCT00271492.
No takes yet. Share an insight, caveat, or question.
Reriani et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: